Coronavirus

March 16th, 2020

Coronavirus.

We are receiving a lot of questions about thyroid cancer and Corona Virus .
Our expert medical team are preparing a statement but for those who have had curative surgery and are without other health problems should not be at any higher risk than the general public.
For other patients if you have concerns please contact your hospital team.

World Thyroid Cancer Rome June 2019

July 8th, 2019

World Thyroid Cancer Rome June 2019

BTCT was represented at the World Congress on Thyroid Cancer by Consultant Thyroid Cancer Surgeon Mr Peter Truran FRCS from the Royal Victoria Infirmary in Newcastle.
Pete presented our work on the update of RAI rooms across the UK to make the patient experience better.

Pete says :
The conference kicked off with a brilliant session on thyroid cancer guidelines updates. This grounded all the doctors with a discussion about ‘where we are now’ and is a great place to start a conference like this. It is only by understanding current evidence and guidelines that can we hope to build and improve on them. Emphasis was on comparing guidelines across the world in including the BTA and broadly the guidelines are similar across the world with only subtle differences. This is reassuring that multiple experts in different countries have reviewed the evidence and arrived at the same conclusions.

This was followed by a discussion around real-life cases.

In the afternoon I presented the BTCT survey and radioiodine room improvement work to the conference. This was well received and many doctors from around the world admired the work that Butterfly has done in this area in so many UK centres. It has been a real privilege to present this work on behalf of Butterfly Thyroid Cancer Trust.

World Thyroid Cancer Rome June 2019 poster

Selimetry Trial

October 26th, 2018

The Selimetry trial has now closed.

There is a new trial underway for patients whose thyroid cancer is no longer responsive the RAI treatment.

Your oncologist will have to ensure that you fit into the criteria necessary for the trial.

You can be referred to any of the following centres .

Bristol Haematology and Oncology Centre
The Christie, Manchester
Churchill Hospital, Oxford
The Royal Marsden, London
University Hospital Southampton
Royal Surrey County Hospital
The Beatson West of Scotland Cancer Centre
Nottingham University Hospitals

You can read about the trial here

New Patient Survey

September 24th, 2018

This study run by the University of Sheffield and Sheffield Teaching Hospitals aims to determine patients’ quality of life following surgery for either thyroid or parathyroid disease. The survey will take 10 minutes to complete.

The focus of this study is to look in depth at the effect of low blood calcium levels, one of the potential side effects of this type of surgery, has on quality of life. Our research group is working on new ways of reducing this side effect of surgery.

We would be very grateful if any patient who has had thyroid or parathyroid surgery could complete the survey, regardless of whether they themselves have ever had low blood calcium levels.
Here is the link :

https://redcap.shef.ac.uk/surveys/?s=PYKF74KHFF

A new clinical trial for people whose thyroid cancer is deemed low risk

August 6th, 2018
A new clinical trial is being proposed for people whose thyroid cancer is deemed ‘low risk and we would like to know how patients feel about this .
If you were told that your thyroid cancer when you were given the diagnosis please could you help us by taking this short survey?
Many thanks ! 
 

NICE decision on Lenvatenib and Sorafenib

July 13th, 2018
NICE have finally given their decision on Lenvatenib and Sorafenib.
Both drugs are recommended for the treatment of thyroid cancer which is no longer taking up RAI.
However,patients can only have access to one of the drugs.
This means that patients who are already taking Sorafenib will not be able to have Lenvatenib when and if they need it.
This is a dreadful decision.
The only exception is if a patient had has Sorafenib and had to withdraw from it due to toxicity.
We await comments from NHS E England on this .